肝炎相关再生障碍性贫血与非肝炎相关再生障碍性贫血的造血干细胞移植:倾向性评分匹配分析
该研究回顾性分析了260例接受造血干细胞移植的获得性再生障碍性贫血患者,经倾向性评分匹配纳入30例肝炎相关再生障碍性贫血(HAAA)患者和90例非HAAA患者。HAAA组移植后5年总生存率、无失败生存率、无GVHD无失败生存率略低于非HAAA组但无统计学差异,两组植入、严重感染、CMV或EB病毒血症及GVHD发生率无显著差异。HAAA患者按供者类型分层后生存、移植相关死亡及GVHD累积发生率无显著差异,单倍体供者移植CMV血症更常见但早期CMV病发生率低。
要点
- HAAA组与非HAAA组移植后5年总生存率、无失败生存率、无GVHD无失败生存率无统计学差异。
- 两组植入、移植后严重感染、CMV或EB病毒血症及GVHD发生率无显著差异。
- HAAA患者中单倍体供者移植CMV血症发生率高于同胞全合供者移植,但早期CMV病发生率低。
核心结论
- 在平衡潜在混杂因素后,HAAA患者移植后结局与非HAAA患者相当,单倍体造血干细胞移植可为HAAA提供替代性治愈选择。
研究设计与样本
- 回顾性研究,复习260例因获得性再生障碍性贫血接受造血干细胞移植的患者,经倾向性评分匹配最终纳入30例HAAA患者和90例非HAAA患者。
主要发现
- HAAA组与非HAAA组移植后5年总生存率分别为75.8%与86.5%(p=0.409),无失败生存率分别为74.0%与83.2%(p=0.485),无GVHD无失败生存率分别为61.2%与67.6%(p=0.669),HAAA组略低但无统计学差异。
- 两组在植入、移植后严重感染、巨细胞病毒(CMV)或EB病毒血症及GVHD发生率方面均无显著差异。
- 两组免疫重建模式大致一致。
- HAAA患者按供者类型分层,生存、移植相关死亡或GVHD累积发生率无显著差异。
- CMV血症在单倍体供者(HID)移植中较同胞全合供者移植更常见(68.7% vs 8.3%,p=0.009),但早期CMV病发生率低(5.6% vs 0.0%,p=1.000)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To validate the efficacy and safety of haematopoietic stem cell transplantation (HSCT) in hepatitis-associated aplastic anaemia (HAAA) patients, we reviewed 260 patients who underwent HSCT for acquired aplastic anaemia and eventually included 30 HAAA patients and 90 non-HAAA patients using propensity score matching. In the HAAA group, the estimated 5-year overall survival rate (75.8% vs. 86.5%, p = 0.409), failure-free survival (FFS) rate (74.0% vs. 83.2%, p = 0.485), graft-versus-host disease (GVHD)-free FFS rate (61.2% vs. 67.6%, p = 0.669) after HSCT were slightly lower but not statistically significant than those in the non-HAAA group. Both groups did not significantly differ in engraftment, post-transplant severe infection, cytomegalovirus (CMV) or Epstein-Barr virus viraemia, or GVHD incidences. The patterns of immune reconstitution were broadly consistent between the two groups. When stratifying HAAA patients according to donor type, no significant differences in survival, transplant-related mortality, or GVHD cumulative incidences were observed. CMV viraemia (68.7% vs 8.3%, p = 0.009) occurred more commonly in haploidentical donor (HID) transplants than in matched sibling donor transplants. However, early CMV disease incidence (5.6% vs. 0.0%, p = 1.000) was low. Overall, the post-transplant outcomes of HAAA patients were comparable to those of non-HAAA patients after balancing potential confounders, and HID-HSCT can offer an alternative curative option for HAAA.
引用
- Li J, Wang Y, Zhang Y, et al. Haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia and non-hepatitis-associated aplastic anaemia: A propensity score-matched analysis. Br J Haematol. 2023. PMID: 36994699. doi:10.1111/bjh.18779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。